Lanreotide – Uses, Dosage, Side Effects, Interaction Lanreotide is a synthetic polypeptide analog of somatostatin that resembles the native hormone in its ability to suppress levels and activity of growth hormone, insulin, glucagon, and many other gastrointestinal peptides. Because its half-life is longer than somatostatin, lanreotide can be used clinically to treat neuroendocrine tumors that secrete excessive amounts of growth hormone (acromegaly) or other active hormones or neuropeptides. Lanreotide has many side effects including suppression of gall bladder contractility and bile production, and maintenance therapy may cause cholelithiasis and pancreatitis as well accompanying liver injury. Lanreotide Acetate is the acetate salt of a synthetic cyclic octapeptide analog of somatostatin. Lanreotide binds to somatostatin receptors (SSTR), specifically SSTR-2, and also to SSTR-5 with a lesser affinity. However, compare with octreotide, this agent is less potent in inhibiting the release of growth hormone from the pituitary gland. Furthermore, lanreotide has an acute effect on decreasing circulating total and free insulin-like growth factor 1 (IGF-I). This agent is usually given as a prolonged-release microparticle or Autogel formulation for the treatment of acromegaly and to relieve the symptoms of neuroendocrine tumors. Lanreotide is a synthetic cyclic octapeptide analog of somatostatin. Lanreotide binds to somatostatin receptors (SSTR), specifically SSTR-2 and also to SSTR-5 with a lesser affinity. However, compare with octreotide, this agent is less potent in inhibiting the release of growth hormone from the pituitary gland. Furthermore, lanreotide has an acute effect on decreasing circulating total and free insulin-like growth factor 1 (IGF-I). This agent is usually given as a prolonged-release microparticle or Autogel formulation for the treatment of acromegaly and to relieve the symptoms of neuroendocrine tumors. Lanreotide Acetate is the acetate salt of a synthetic cyclic octapeptide analog of somatostatin. Lanreotide binds to somatostatin receptors (SSTR), specifically SSTR-2, and also to SSTR-5 with a lesser affinity. However, compare with octreotide, this agent is less potent in inhibiting the release of growth hormone from the pituitary gland. Furthermore, lanreotide has an acute effect on decreasing circulating total and free insulin-like growth factor 1 (IGF-I). This agent is usually given as a prolonged-release microparticle or Autogel formulation for the treatment of acromegaly and to relieve the symptoms of neuroendocrine tumors. Lanreotide is a drug employed in the management of acromegaly (a hormonal condition caused by excess growth hormone) in addition to symptoms caused by neuroendocrine tumors, especially carcinoid syndrome. This drug is a long-acting analog of the drug somatostatin, a growth hormone inhibitor. Lanreotide is manufactured by the company, Ipsen Pharmaceuticals as lanreotide acetate, and marketed as Somatuline. It is approved in several countries worldwide, including the United Kingdom, Australia, and Canada. Lanreotide was first approved for use in the United States by the FDA on August 30, 2007. Mechanism of Action Lanreotide is a somatostatin analog (SSA) and has mainly inhibitory effects which are mediated via somatostatin receptors (SSTRs) 2 and 5 and include inhibition of growth hormone release in the brain. Tumor SSTR activation induces downstream cell cycle arrest and/or apoptosis, and also results in blunted production of substances that support tumor growth as well as tumor angiogenesis. This leads to the antiproliferative effects of Lanreotide. Lanreotide exhibits antisecretory effects through cAMP suppression and activation of ion currents such as K+ and Ca2+ which leads to hyperpolarization of the membrane and inhibition of Ca2+-mediated depolarization. Furthermore, through direct and indirect mechanisms, Lanreotide has potent antiproliferative effects. Indications Lanreotide is indicated for the long-term treatment of patients with acromegaly who have had an inadequate response to, or cannot be treated with, surgery and/or radiotherapy. It is also indicated in the treatment of adult patients with unresectable, well- or moderately-differentiated, locally advanced, or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) to improve progression-free survival. Lanreotide is additionally indicated for the treatment of adults with carcinoid syndrome – when used, it reduces the frequency of short-acting somatostatin analog rescue therapy. Lanreotide is a somatostatin analog used for the treatment of unresectable, well- or moderately-differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors and acromegaly. Treatment of acromegaly, Treatment of gastrointestinal fistulae, Treatment of metastases to the peritoneum, Treatment of pituitary gigantism, Treatment of pituitary neoplasms Lanreotide is a synthetic polypeptide analog of somatostatin that resembles the native hormone in its ability to suppress levels and activity of growth hormone, insulin, glucagon, and many other gastrointestinal peptides. Because its half-life is longer than somatostatin, lanreotide can be used clinically to treat neuroendocrine tumors that secrete excessive amounts of growth hormone (acromegaly) or other active hormones or neuropeptides. Lanreotide is used in the treatment of acromegaly, due to both pituitary and non-pituitary growth hormone-secreting tumors, and the management of symptoms caused by neuroendocrine tumors, particularly carcinoid tumors, and VIPomas. In the United States and Canada, lanreotide is only indicated for the treatment of acromegaly. In the United Kingdom, it is also indicated in the treatment of thyrotrophic adenoma,[rx] a rare tumor of the pituitary gland which secretes TSH. Lanreotide also shows activity against non-endocrine tumors, and, along with other somatostatin analogs, is being studied as a possible general antitumor agent. Acromegaly Carcinoid Syndrome Unresectable, locally advanced enteropancreatic neuroendocrine tumors Unresectable, locally advanced well- or moderately-differentiated Gastroenteropancreatic Neuroendocrine Tumors Unresectable, metastatic enteropancreatic neuroendocrine tumors Unresectable, metastatic well- or moderately-differentiated Gastroenteropancreatic Neuroendocrine Tumors Use in Cancer Lanreotide acetate is approved to treat: Gastroenteropancreatic neuroendocrine tumors. It is used in some adults whose tumors cannot be removed by surgery, is locally advanced, or have metastasized (spread to other parts of the body). Carcinoid syndrome in adults. Lanreotide acetate is also being studied in the treatment of other conditions or types of cancer. Contraindications Bradycardia, cardiac disease. Use lanreotide with caution in patients with underlying cardiac disease or preexisting bradycardia. Diabetes mellitus. Gallbladder disease. Hepatic disease. Hypothyroidism, thyroid disease. Pregnancy. Infertility, reproductive risk. Breast-feeding. a condition with low thyroid hormone levels low blood sugar high blood pressure slow heartbeat liver problems gallstones disease of the gallbladder high blood sugar a patient who is producing milk and breastfeeding chronic kidney disease stage 3A (moderate) chronic kidney disease stage 3B (moderate) chronic kidney disease stage 4 (severe) chronic kidney disease stage 5 (failure) kidney disease with likely reduction in kidney function Dosage Strengths: 60 mg/0.2 mL; 90 mg/0.3 mL; 120 mg/0.5 mL Acromegaly Initial dose: 90 mg, by deep subcutaneous injection, every 4 weeks for 3 months The goal of treatment is to reduce growth hormone (GH) and insulin-like growth factor (IGF-1) levels to normal. Adjust dose after initial 3 months. No dose adjustment is required for elderly patients. Long-term treatment of acromegalic patients who have had an inadequate response to surgery and/or radiotherapy, or for whom surgery and/or radiotherapy is not an option. Neuroendocrine Carcinoma 120 mg, by deep subcutaneous injection, every 4 weeks No dose adjustment is required for elderly patients. Treatment of patients with unresectable, well or moderately-differentiated, locally advanced, or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) to improve progression-free survival. Carcinoid Syndrome 120 mg by deep subcutaneous injection every 4 weeks If patients are already being treated for GEP-NETs, do not administer an additional dose for the treatment of carcinoid syndrome. For the treatment of carcinoid syndrome; when used, it reduces the frequency of short-acting somatostatin analog rescue therapy. Renal Dose Adjustments Acromegaly: Moderate to severe renal impairment: Initial dose: 60 mg, by deep subcutaneous injection, every 4 weeks for 3 months, followed by dose adjustments as described for non-really impaired patients. Use caution when considering an extended dosing interval (120 mg every 6 or 8 weeks) in moderate or severe renal impairment. Gastroenteropancreatic Neuroendocrine Tumors: No adjustment is recommended for mild to moderate renal impairment Data not available for severe renal impairment Liver Dose Adjustments Acromegaly: Moderate to severe hepatic impairment: Initial dose: 60 mg, by deep subcutaneous injection, every 4 weeks for 3 months, followed by dose adjustments as described for non-hepatically impaired patients. Gastroenteropancreatic Neuroendocrine Tumors: Data not available for any level of hepatic impairment Dose Adjustments Acromegaly: After the initial 3 month dosing, adjust dose based on growth hormone (GH) and insulin-like growth factor (IGF-1) levels: GH over 1 and up to 2.5 ng/mL, IGF-1 normal, and symptoms controlled: 90 mg, by deep subcutaneous (SC) injection, every 4 weeks GH over 2.5 ng/mL, IGF-1 elevated, and/or symptoms uncontrolled: 120 mg, by deep SC injection, every 4 weeks GH less than 1 ng/mL, IGF-1 normal, symptoms controlled: 60 mg, by deep SC injection, every 4 weeks Adjust dose according to patient response, as judged by a reduction in GH and/or IGF-1 levels, and/or changes in acromegaly symptoms. Patients controlled on 60 mg or 90 mg may be considered for an extended dosing interval of 120 mg every 6 or 8 weeks; obtain GH and IGF-1 levels 6 weeks after this change to evaluate persistence of patient response. Continued monitoring of patient response with dose adjustments for biochemical and clinical symptom control, as necessary, is recommended. No dose adjustment is required for elderly patients. No difference in safety and effectiveness was seen in elderly patients, however greater sensitivity cannot be ruled out. In general, dose selection for elderly patient should be cautious, starting at the low end of the dosing range. No dose adjustment is required for elderly patients. Administration advice: Healthcare providers should administer this drug. Administer in the superior external quadrant of the buttock; alternate between right and left sides with each injection. Remove from refrigerator 30 minutes before administration, but keep pouch sealed until ready to administer. Side Effects The Most Common diarrhea loose stools constipation gas vomiting weight loss headache redness, pain, itching, or a lump at the injection site depression pain in the upper right part of the stomach, center of the stomach, back, or shoulder muscle pain or discomfort yellowing of the skin and eyes fever with chills nausea swelling of the face, throat, tongue, lips, or eyes tightness in the throat difficulty breathing and swallowing wheezing hoarseness rash itching hives shortness of breath slowed or irregular heartbeat More common Blurred vision chest pain or discomfort dizziness gaseous abdominal or stomach pain headache lightheadedness, dizziness, or fainting nervousness pale skin pounding in the ears recurrent fever slow, fast, or irregular heartbeat stomach fullness troubled breathing with exertion unusual bleeding or bruising unusual tiredness or weakness yellow eyes or skin Difficulty having a bowel movement difficulty with moving excess air or gas in the stomach or bowels feeling of fullness inflammation, itching, lumps, or pain at the injection site muscle pain or stiffness pain in the joints passing gas weight loss Rare Bloating chills clay-colored stools confusion constipation cough dark urine diarrhea difficulty swallowing dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position fat in the stool fever hives, itching, skin rash indigestion large, hive-like swelling on face, eyelids, lips, tongue, throat, hands, legs, feet, or genitals loss of appetite nausea pains in the stomach, side, or abdomen, possibly radiating to the back puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue severe nausea or vomiting stomach pain or cramps sudden loss of weight sweating tightness in the chest unusual drowsiness, dullness, or feeling of sluggishness vomiting You Might Also Read Indacaterol; Indications/Uses, Side effects, Drug Interactions, PregnancyDrug Interactions DRUG INTERACTION Abemaciclib The metabolism of Abemaciclib can be decreased when combined with Lanreotide. Acalabrutinib The metabolism of Acalabrutinib can be decreased when combined with Lanreotide. Acarbose The therapeutic efficacy of Acarbose can be decreased when used in combination with Lanreotide. Acebutolol Acebutolol may increase the bradycardic activities of Lanreotide. Acenocoumarol The serum concentration of Acenocoumarol can be increased when it is combined with Lanreotide. Acetohexamide The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Lanreotide. Albendazole The metabolism of Albendazole can be decreased when combined with Lanreotide. Albiglutide The therapeutic efficacy of Albiglutide can be decreased when used in combination with Lanreotide. Alectinib The metabolism of Alectinib can be decreased when combined with Lanreotide. Alfentanil Alfentanil may increase the bradycardic activities of Lanreotide. Alfuzosin The metabolism of Alfuzosin can be decreased when combined with Lanreotide. Alogliptin The therapeutic efficacy of Alogliptin can be decreased when used in combination with Lanreotide. Alpelisib The metabolism of Alpelisib can be decreased when combined with Lanreotide. Alprazolam The metabolism of Alprazolam can be decreased when combined with Lanreotide. Aminophylline The metabolism of Aminophylline can be decreased when combined with Lanreotide. Amiodarone The metabolism of Amiodarone can be decreased when combined with Lanreotide. Amlodipine Amlodipine may increase the bradycardic activities of Lanreotide. Aripiprazole The metabolism of Aripiprazole can be decreased when combined with Lanreotide. Aripiprazole The metabolism of Aripiprazole lauroxil can be decreased when combined with Lanreotide. Articaine The risk or severity of methemoglobinemia can be increased when Lanreotide is combined with Articaine. Astemizole The metabolism of Astemizole can be decreased when combined with Lanreotide. Atazanavir The metabolism of Atazanavir can be decreased when combined with Lanreotide. Atenolol Atenolol may increase the bradycardic activities of Lanreotide. Atorvastatin The metabolism of Atorvastatin can be decreased when combined with Lanreotide. Axitinib The metabolism of Axitinib can be decreased when combined with Lanreotide. Azithromycin The metabolism of Azithromycin can be decreased when combined with Lanreotide. Bendroflumethi Bendroflumethiazide may increase the bradycardic activities of Lanreotide. Benzocaine The risk or severity of methemoglobinemia can be increased when Lanreotide is combined with Benzocaine. Benzyl alcohol The risk or severity of methemoglobinemia can be increased when Lanreotide is combined with Benzyl alcohol. Bepridil Bepridil may increase the bradycardic activities of Lanreotide. Beractant Beractant may increase the bradycardic activities of Lanreotide. Betaxolol Betaxolol may increase the bradycardic activities of Lanreotide. Bicalutamide The metabolism of Bicalutamide can be decreased when combined with Lanreotide. Bisoprolol Bisoprolol may increase the bradycardic activities of Lanreotide. Bortezomib The metabolism of Bortezomib can be decreased when combined with Lanreotide. Bosutinib The metabolism of Bosutinib can be decreased when combined with Lanreotide. Brentuximab vedotin The metabolism of Brentuximab vedotin can be decreased when combined with Lanreotide. Bretylium Bretylium may increase the bradycardic activities of Lanreotide. Brigatinib The metabolism of Brigatinib can be decreased when combined with Lanreotide. Bromocriptine The serum concentration of Bromocriptine can be increased when it is combined with Lanreotide. Bupivacaine The risk or severity of methemoglobinemia can be increased when Lanreotide is combined with Bupivacaine. Busulfan The metabolism of Busulfan can be decreased when combined with Lanreotide. Butacaine The risk or severity of methemoglobinemia can be increased when Lanreotide is combined with Butacaine. Butamben The risk or severity of methemoglobinemia can be increased when Lanreotide is combined with Butamben. Cabazitaxel The metabolism of Cabazitaxel can be decreased when combined with Lanreotide. Cabergoline The metabolism of Cabergoline can be decreased when combined with Lanreotide. Calfactant Calfactant may increase the bradycardic activities of Lanreotide. Canagliflozin The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Lanreotide. Capsaicin The risk or severity of methemoglobinemia can be increased when Lanreotide is combined with Capsaicin. Carbamazepine The metabolism of Carbamazepine can be decreased when combined with Lanreotide. Carvedilol Carvedilol may increase the bradycardic activities of Lanreotide. Celiprolol Celiprolol may increase the bradycardic activities of Lanreotide. Cephalexin The metabolism of Cephalexin can be decreased when combined with Lanreotide. Ceritinib Lanreotide may increase the bradycardic activities of Ceritinib. Chloroprocaine The risk or severity of methemoglobinemia can be increased when Lanreotide is combined with Chloroprocaine. Chlorpromazine The metabolism of Chlorpromazine can be decreased when combined with Lanreotide. Chlorpropamide The therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Lanreotide. Cilostazol The metabolism of Cilostazol can be decreased when combined with Lanreotide. Cinchocaine The risk or severity of methemoglobinemia can be increased when Lanreotide is combined with Cinchocaine. Cinnarizine Cinnarizine may increase the bradycardic activities of Lanreotide. Cisapride The metabolism of Cisapride can be decreased when combined with Lanreotide. Citalopram The risk or severity of hypoglycemia can be increased when Citalopram is combined with Lanreotide. Clevidipine Clevidipine may increase the bradycardic activities of Lanreotide. Clomipramine The metabolism of Clomipramine can be decreased when combined with Lanreotide. Clonidine The metabolism of Clonidine can be decreased when combined with Lanreotide. Clozapine The serum concentration of Clozapine can be increased when it is combined with Lanreotide. Cobimetinib The metabolism of Cobimetinib can be decreased when combined with Lanreotide. Cocaine The risk or severity of methemoglobinemia can be increased when Lanreotide is combined with Cocaine. Colchicine The metabolism of Colchicine can be decreased when combined with Lanreotide. Conivaptan The metabolism of Conivaptan can be decreased when combined with Lanreotide. Copanlisib The metabolism of Copanlisib can be decreased when combined with Lanreotide. Copper oxodotre The therapeutic efficacy of Lanreotide can be decreased when used in combination with Copper oxodotreotide Cu-64. Crizotinib Crizotinib may increase the bradycardic activities of Lanreotide. Cyclandelate Cyclandelate may increase the bradycardic activities of Lanreotide. Cyclophosphamide The metabolism of Cyclophosphamide can be decreased when combined with Lanreotide. Cyclosporine The bioavailability of Cyclosporine can be decreased when combined with Lanreotide. Dabrafenib The metabolism of Dabrafenib can be decreased when combined with Lanreotide. Dacomitinib The metabolism of Dacomitinib can be decreased when combined with Lanreotide. Dapagliflozin The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Lanreotide. Darbepoetin alfa The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Lanreotide. Dasatinib The metabolism of Dasatinib can be decreased when combined with Lanreotide. Desvenlafaxine The risk or severity of hypoglycemia can be increased when Desvenlafaxine is combined with Lanreotide. Dexmedetomidine Dexmedetomidine may increase the bradycardic activities of Lanreotide. Digitoxin The metabolism of Digitoxin can be decreased when combined with Lanreotide. Digoxin Digoxin may increase the bradycardic activities of Lanreotide. Dihydroergocornine The metabolism of Dihydroergocornine can be decreased when combined with Lanreotide. Dihydroergocristine The metabolism of Dihydroergocristine can be decreased when combined with Lanreotide. Dihydroergotamine The metabolism of Dihydroergotamine can be decreased when combined with Lanreotide. Diltiazem Diltiazem may increase the bradycardic activities of Lanreotide. Diphenhydramine The risk or severity of methemoglobinemia can be increased when Lanreotide is combined with Diphenhydramine. Disopyramide The therapeutic efficacy of Disopyramide can be decreased when used in combination with Lanreotide. Docetaxel The metabolism of Docetaxel can be decreased when combined with Lanreotide. Dofetilide The metabolism of Dofetilide can be decreased when combined with Lanreotide. Donepezil Donepezil may increase the bradycardic activities of Lanreotide. Dotatate gallium Lanreotide may decrease effectiveness of Dotatate gallium Ga-68 as a diagnostic agent. Doxazosin The metabolism of Doxazosin can be decreased when combined with Lanreotide. Doxorubicin The metabolism of Doxorubicin can be decreased when combined with Lanreotide. Dronabinol The serum concentration of Dronabinol can be increased when it is combined with Lanreotide. Dronedarone The metabolism of Dronedarone can be decreased when combined with Lanreotide. Drospirenone The metabolism of Drospirenone can be decreased when combined with Lanreotide. Dulaglutide The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Lanreotide. Duloxetine The risk or severity of hypoglycemia can be increased when Duloxetine is combined with Lanreotide. Duvelisib The metabolism of Duvelisib can be decreased when combined with Lanreotide. Dyclonine The risk or severity of methemoglobinemia can be increased when Lanreotide is combined with Dyclonine. Ebastine The metabolism of Ebastine can be decreased when combined with Lanreotide. Edotreotide Lanreotide may decrease effectiveness of Edotreotide gallium Ga-68 as a diagnostic agent. Elexacaftor The metabolism of Elexacaftor can be decreased when combined with Lanreotide. Eliglustat The metabolism of Eliglustat can be decreased when combined with Lanreotide. Empagliflozin The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Lanreotide. Enasidenib The metabolism of Enasidenib can be decreased when combined with Lanreotide. Entrectinib The metabolism of Entrectinib can be decreased when combined with Lanreotide. Enzalutamide The serum concentration of Enzalutamide can be increased when it is combined with Lanreotide. Erdafitinib The metabolism of Erdafitinib can be decreased when combined with Lanreotide. Ergotamine The metabolism of Ergotamine can be decreased when combined with Lanreotide. Erlotinib The metabolism of Erlotinib can be decreased when combined with Lanreotide. Ertugliflozin The therapeutic efficacy of Ertugliflozin can be decreased when used in combination with Lanreotide. Erythropoietin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Lanreotide. Escitalopram The risk or severity of hypoglycemia can be increased when Escitalopram is combined with Lanreotide. Esmolol Esmolol may increase the bradycardic activities of Lanreotide. Estetrol The metabolism of Estetrol can be decreased when combined with Lanreotide. Eszopiclone The metabolism of Eszopiclone can be decreased when combined with Lanreotide. Ethosuximide Ethosuximide may increase the bradycardic activities of Lanreotide. Ethyl chloride The risk or severity of methemoglobinemia can be increased when Lanreotide is combined with Ethyl chloride. Etidocaine The risk or severity of methemoglobinemia can be increased when Lanreotide is combined with Etidocaine. Etoposide The metabolism of Etoposide can be decreased when combined with Lanreotide. Everolimus The metabolism of Everolimus can be decreased when combined with Lanreotide. Exenatide The therapeutic efficacy of Exenatide can be decreased when used in combination with Lanreotide. Felodipine Felodipine may increase the bradycardic activities of Lanreotide. Fenofibrate The metabolism of Fenofibrate can be decreased when combined with Lanreotide. Fentanyl Fentanyl may increase the bradycardic activities of Lanreotide. Fexinidazole The risk or severity of adverse effects can be increased when Lanreotide is combined with Fexinidazole. Finerenone The serum concentration of Finerenone can be increased when it is combined with Lanreotide. Fingolimod Lanreotide may increase the bradycardic activities of Fingolimod. Flunarizine Flunarizine may increase the bradycardic activities of Lanreotide. Fluoxetine The risk or severity of hypoglycemia can be increased when Fluoxetine is combined with Lanreotide. Fluspirilene Fluspirilene may increase the bradycardic activities of Lanreotide. Fluvoxamine The risk or severity of hypoglycemia can be increased when Fluvoxamine is combined with Lanreotide. Fosaprepitant The metabolism of Fosaprepitant can be decreased when combined with Lanreotide. Fosphenytoin The metabolism of Fosphenytoin can be decreased when combined with Lanreotide. Galantamine Galantamine may increase the bradycardic activities of Lanreotide. Gatifloxacin The risk or severity of hypoglycemia can be increased when Gatifloxacin is combined with Lanreotide. Gilteritinib The metabolism of Gilteritinib can be decreased when combined with Lanreotide. Gliclazide The therapeutic efficacy of Gliclazide can be decreased when used in combination with Lanreotide. Glimepiride The therapeutic efficacy of Glimepiride can be decreased when used in combination with Lanreotide. Glipizide The therapeutic efficacy of Glipizide can be decreased when used in combination with Lanreotide. Gliquidone The therapeutic efficacy of Gliquidone can be decreased when used in combination with Lanreotide. Glyburide The therapeutic efficacy of Glyburide can be decreased when used in combination with Lanreotide. Glymidine The therapeutic efficacy of Glymidine can be decreased when used in combination with Lanreotide. Guanfacine Guanfacine may increase the bradycardic activities of Lanreotide. Haloperidol The serum concentration of Haloperidol can be increased when it is combined with Lanreotide. Ibrutinib The metabolism of Ibrutinib can be decreased when combined with Lanreotide. Idelalisib The metabolism of Idelalisib can be decreased when combined with Lanreotide. Ifosfamide The metabolism of Ifosfamide can be decreased when combined with Lanreotide. Iloperidone The metabolism of Iloperidone can be decreased when combined with Lanreotide. Indomethacin The risk or severity of hypoglycemia can be increased when Indomethacin is combined with Lanreotide. Infigratinib The metabolism of Infigratinib can be decreased when combined with Lanreotide. Insulin aspart The risk or severity of hypoglycemia can be increased when Lanreotide is combined with Insulin aspart. Insulin beef The risk or severity of hypoglycemia can be increased when Lanreotide is combined with Insulin beef. Insulin degludec The risk or severity of hypoglycemia can be increased when Lanreotide is combined with Insulin degludec. Insulin detemir The risk or severity of hypoglycemia can be increased when Lanreotide is combined with Insulin detemir. Insulin glargine The risk or severity of hypoglycemia can be increased when Lanreotide is combined with Insulin glargine. Insulin glulisine The risk or severity of hypoglycemia can be increased when Lanreotide is combined with Insulin glulisine. Insulin human The risk or severity of hypoglycemia can be increased when Lanreotide is combined with Insulin human. Insulin lispro The risk or severity of hypoglycemia can be increased when Lanreotide is combined with Insulin lispro. Insulin pork The risk or severity of hypoglycemia can be increased when Lanreotide is combined with Insulin pork. Irinotecan The metabolism of Irinotecan can be decreased when combined with Lanreotide. Isavuconazole The metabolism of Isavuconazole can be decreased when combined with Lanreotide. Isradipine Isradipine may increase the bradycardic activities of Lanreotide. Ivabradine Lanreotide may increase the bradycardic activities of Ivabradine. Ivosidenib The metabolism of Ivosidenib can be decreased when combined with Lanreotide. Ixabepilone The metabolism of Ixabepilone can be decreased when combined with Lanreotide. Ixazomib The metabolism of Ixazomib can be decreased when combined with Lanreotide. Labetalol Labetalol may increase the bradycardic activities of Lanreotide. Lacidipine Lanreotide may increase the bradycardic activities of Lacidipine. Lacosamide Lacosamide may increase the bradycardic activities of Lanreotide. Lamotrigine Lamotrigine may increase the bradycardic activities of Lanreotide. Lasmiditan Lasmiditan may increase the bradycardic activities of Lanreotide. Lefamulin The metabolism of Lefamulin can be decreased when combined with Lanreotide. Lercanidipine Lercanidipine may increase the bradycardic activities of Lanreotide. Levacetylmethadol The metabolism of Levacetylmethadol can be decreased when combined with Lanreotide. Levamlodipine The serum concentration of Levamlodipine can be increased when it is combined with Lanreotide. Levobetaxolol Lanreotide may increase the bradycardic activities of Levobetaxolol. Levobupivacaine The risk or severity of methemoglobinemia can be increased when Lanreotide is combined with Levobupivacaine. Levomenthol Levomenthol may increase the bradycardic activities of Lanreotide. Levomilnacipran The risk or severity of hypoglycemia can be increased when Lanreotide is combined with Levomilnacipran. Lidocaine The risk or severity of methemoglobinemia can be increased when Lanreotide is combined with Lidocaine. Lidoflazine Lanreotide may increase the bradycardic activities of Lidoflazine. Linagliptin The therapeutic efficacy of Linagliptin can be decreased when used in combination with Lanreotide. Lipoic acid The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Lanreotide. Liraglutide The therapeutic efficacy of Liraglutide can be decreased when used in combination with Lanreotide. Lixisenatide The therapeutic efficacy of Lixisenatide can be decreased when used in combination with Lanreotide. Lomitapide The metabolism of Lomitapide can be decreased when combined with Lanreotide. Loperamide Loperamide may increase the bradycardic activities of Lanreotide. Lovastatin The metabolism of Lovastatin can be decreased when combined with Lanreotide. Lucinactant Lucinactant may increase the bradycardic activities of Lanreotide. Lutetium Lu The therapeutic efficacy of Lutetium Lu 177 dotatate can be decreased when used in combination with Lanreotide. Macimorelin The therapeutic efficacy of Macimorelin can be decreased when used in combination with Lanreotide. Magnesium sulfate Magnesium sulfate may increase the bradycardic activities of Lanreotide. Manidipine Lanreotide may increase the bradycardic activities of Manidipine. Mecasermin The therapeutic efficacy of Mecasermin can be decreased when used in combination with Lanreotide. You Might Also Read Psyllium Husk Benefits - Side Effects, Interactions Meloxicam The risk or severity of methemoglobinemia can be increased when Lanreotide is combined with Meloxicam. Meperidine The metabolism of Meperidine can be decreased when combined with Lanreotide. Mepivacaine The risk or severity of methemoglobinemia can be increased when Lanreotide is combined with Mepivacaine. Metformin The therapeutic efficacy of Metformin can be decreased when used in combination with Lanreotide. Methotrexate The metabolism of Methotrexate can be decreased when combined with Lanreotide. Methoxy The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Lanreotide. Methsuximide Methsuximide may increase the bradycardic activities of Lanreotide. Methyldopa Methyldopa may increase the bradycardic activities of Lanreotide. Methylprednisone The metabolism of Methylprednisone can be decreased when combined with Lanreotide. Methysergide The metabolism of Methysergide can be decreased when combined with Lanreotide. Metoprolol Metoprolol may increase the bradycardic activities of Lanreotide. Midazolam The serum concentration of Midazolam can be increased when it is combined with Lanreotide. Midodrine Midodrine may increase the bradycardic activities of Lanreotide. Midostaurin The metabolism of Midostaurin can be decreased when combined with Lanreotide. Mifepristone The therapeutic efficacy of Mifepristone can be decreased when used in combination with Lanreotide. Miglitol The therapeutic efficacy of Miglitol can be decreased when used in combination with Lanreotide. Milnacipran The risk or severity of hypoglycemia can be increased when Milnacipran is combined with Lanreotide. Nadolol Nadolol may increase the bradycardic activities of Lanreotide. Nateglinide The therapeutic efficacy of Nateglinide can be decreased when used in combination with Lanreotide. Nebivolol Nebivolol may increase the bradycardic activities of Lanreotide. Nefazodone The risk or severity of hypoglycemia can be increased when Nefazodone is combined with Lanreotide. Neratinib The metabolism of Neratinib can be decreased when combined with Lanreotide. Netupitant The metabolism of Netupitant can be decreased when combined with Lanreotide. Nicardipine Nicardipine may increase the bradycardic activities of Lanreotide. Nifedipine Nifedipine may increase the bradycardic activities of Lanreotide. Nilotinib The metabolism of Nilotinib can be decreased when combined with Lanreotide. Nilvadipine Nilvadipine may increase the bradycardic activities of Lanreotide. Nimesulide Nimesulide may increase the bradycardic activities of Lanreotide. Nimodipine Nimodipine may increase the bradycardic activities of Lanreotide. Nintedanib The metabolism of Nintedanib can be decreased when combined with Lanreotide. Nisoldipine Nisoldipine may increase the bradycardic activities of Lanreotide. Nitrendipine Nitrendipine may increase the bradycardic activities of Lanreotide. Norethisterone The metabolism of Norethisterone can be decreased when combined with Lanreotide. Nortriptyline The metabolism of Nortriptyline can be decreased when combined with Lanreotide. Nylidrin Nylidrin may increase the bradycardic activities of Lanreotide. Octreotide The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Lanreotide. Olaparib The metabolism of Olaparib can be decreased when combined with Lanreotide. Osimertinib The metabolism of Osimertinib can be decreased when combined with Lanreotide. Oxetacaine The risk or severity of methemoglobinemia can be increased when Lanreotide is combined with Oxetacaine. Oxprenolol Oxprenolol may increase the bradycardic activities of Lanreotide. Oxybuprocaine The risk or severity of methemoglobinemia can be increased when Lanreotide is combined with Oxybuprocaine. Paclitaxel The metabolism of Paclitaxel can be decreased when combined with Lanreotide. Palbociclib The metabolism of Palbociclib can be decreased when combined with Lanreotide. Panobinostat The metabolism of Panobinostat can be decreased when combined with Lanreotide. Paroxetine The risk or severity of hypoglycemia can be increased when Paroxetine is combined with Lanreotide. Pasireotide The risk or severity of hypoglycemia can be increased when Pasireotide is combined with Lanreotide. Pazopanib The metabolism of Pazopanib can be decreased when combined with Lanreotide. Peginesatide The risk or severity of Thrombosis can be increased when Peginesatide is combined with Lanreotide. Pegvisomant The risk or severity of increased transaminases can be increased when Lanreotide is combined with Pegvisomant. Penbutolol Penbutolol may increase the bradycardic activities of Lanreotide. Pentamidine The therapeutic efficacy of Pentamidine can be decreased when used in combination with Lanreotide. Perhexiline Perhexiline may increase the bradycardic activities of Lanreotide. Pexidartinib The metabolism of Pexidartinib can be decreased when combined with Lanreotide. Phenformin The therapeutic efficacy of Phenformin can be decreased when used in combination with Lanreotide. Phenol The risk or severity of methemoglobinemia can be increased when Lanreotide is combined with Phenol. Phenprocoumon The metabolism of Phenprocoumon can be decreased when combined with Lanreotide. Pimavanserin The metabolism of Pimavanserin can be decreased when combined with Lanreotide. Pimozide The metabolism of Pimozide can be decreased when combined with Lanreotide. Pinaverium Lanreotide may increase the bradycardic activities of Pinaverium. Pindolol Pindolol may increase the bradycardic activities of Lanreotide. Pioglitazone The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Lanreotide. Pomalidomide The metabolism of Pomalidomide can be decreased when combined with Lanreotide. Ponatinib The metabolism of Ponatinib can be decreased when combined with Lanreotide. Ponesimod The risk or severity of bradycardia can be increased when Ponesimod is combined with Lanreotide. Poractant alfa Lanreotide may increase the bradycardic activities of Poractant alfa. Practolol Practolol may increase the bradycardic activities of Lanreotide. Pramlintide The therapeutic efficacy of Pramlintide can be decreased when used in combination with Lanreotide. Pramocaine The risk or severity of methemoglobinemia can be increased when Lanreotide is combined with Pramocaine. Pregabalin The risk or severity of hypoglycemia can be increased when Pregabalin is combined with Lanreotide. Prenylamine Prenylamine may increase the bradycardic activities of Lanreotide. Pretomanid The metabolism of Pretomanid can be decreased when combined with Lanreotide. Prilocaine The risk or severity of methemoglobinemia can be increased when Lanreotide is combined with Prilocaine. Procaine The risk or severity of methemoglobinemia can be increased when Lanreotide is combined with Procaine. Propafenone Propafenone may increase the bradycardic activities of Lanreotide. Proparacaine The risk or severity of methemoglobinemia can be increased when Lanreotide is combined with Proparacaine. Propoxycaine The risk or severity of methemoglobinemia can be increased when Lanreotide is combined with Propoxycaine. Propranolol Propranolol may increase the bradycardic activities of Lanreotide. Prucalopride The metabolism of Prucalopride can be decreased when combined with Lanreotide. Quinidine The metabolism of Quinidine can be decreased when combined with Lanreotide. Quinine The therapeutic efficacy of Quinine can be decreased when used in combination with Lanreotide. Regorafenib The metabolism of Regorafenib can be decreased when combined with Lanreotide. Remifentanil Remifentanil may increase the bradycardic activities of Lanreotide. Repaglinide The therapeutic efficacy of Repaglinide can be decreased when used in combination with Lanreotide. Retapamulin The metabolism of Retapamulin can be decreased when combined with Lanreotide. Ribociclib The metabolism of Ribociclib can be decreased when combined with Lanreotide. Rivastigmine Rivastigmine may increase the bradycardic activities of Lanreotide. Roflumilast The serum concentration of Roflumilast can be increased when it is combined with Lanreotide. Romidepsin The metabolism of Romidepsin can be decreased when combined with Lanreotide. Ropivacaine The risk or severity of methemoglobinemia can be increased when Lanreotide is combined with Ropivacaine. Rosiglitazone The therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Lanreotide. Rosuvastatin The metabolism of Rosuvastatin can be decreased when combined with Lanreotide. Ruxolitinib Ruxolitinib may increase the bradycardic activities of Lanreotide. Saxagliptin The therapeutic efficacy of Saxagliptin can be decreased when used in combination with Lanreotide. Semaglutide The therapeutic efficacy of Semaglutide can be decreased when used in combination with Lanreotide. Sertraline The risk or severity of hypoglycemia can be increased when Sertraline is combined with Lanreotide. Siponimod The metabolism of Siponimod can be decreased when combined with Lanreotide. Sirolimus The metabolism of Sirolimus can be decreased when combined with Lanreotide. Sitagliptin The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Lanreotide. Sonidegib The metabolism of Sonidegib can be decreased when combined with Lanreotide. Sorafenib The metabolism of Sorafenib can be decreased when combined with Lanreotide. You Might Also Read What Is Aluminum Chloride Hexahydrate? Sotagliflozin The therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Lanreotide. Sotalol Sotalol may increase the bradycardic activities of Lanreotide. Sufentanil Sufentanil may increase the bradycardic activities of Lanreotide. Sulfadiazine The therapeutic efficacy of Sulfadiazine can be decreased when used in combination with Lanreotide. Sulfamethoxazole The therapeutic efficacy of Sulfamethoxazole can be decreased when used in combination with Lanreotide. Sulfisoxazole The therapeutic efficacy of Sulfisoxazole can be decreased when used in combination with Lanreotide. Sunitinib The metabolism of Sunitinib can be decreased when combined with Lanreotide. Suvorexant The metabolism of Suvorexant can be decreased when combined with Lanreotide. Tacrolimus The serum concentration of Tacrolimus can be increased when it is combined with Lanreotide. Tamoxifen The metabolism of Tamoxifen can be decreased when combined with Lanreotide. Tasimelteon The metabolism of Tasimelteon can be decreased when combined with Lanreotide. Tazemetostat The metabolism of Tazemetostat can be decreased when combined with Lanreotide. Temsirolimus The metabolism of Temsirolimus can be decreased when combined with Lanreotide. Teniposide The metabolism of Teniposide can be decreased when combined with Lanreotide. Tenofovir alafen The metabolism of Tenofovir alafenamide can be decreased when combined with Lanreotide. Terfenadine The metabolism of Terfenadine can be decreased when combined with Lanreotide. Tetracaine The risk or severity of methemoglobinemia can be increased when Lanreotide is combined with Tetracaine. Theophylline The metabolism of Theophylline can be decreased when combined with Lanreotide. Thiotepa The metabolism of Thiotepa can be decreased when combined with Lanreotide. Timolol Timolol may increase the bradycardic activities of Lanreotide. Tirzepatide The therapeutic efficacy of Tirzepatide can be decreased when used in combination with Lanreotide. Tizanidine Tizanidine may increase the bradycardic activities of Lanreotide. Tofacitinib The metabolism of Tofacitinib can be decreased when combined with Lanreotide. Tolazamide The therapeutic efficacy of Tolazamide can be decreased when used in combination with Lanreotide. Tolbutamide The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Lanreotide. Tolfenamic acid Lanreotide may increase the bradycardic activities of Tolfenamic acid. Tolvaptan The metabolism of Tolvaptan can be decreased when combined with Lanreotide. Trabectedin The metabolism of Trabectedin can be decreased when combined with Lanreotide. Tramadol The metabolism of Tramadol can be decreased when combined with Lanreotide. Trastuzumab The metabolism of Trastuzumab emtansine can be decreased when combined with Lanreotide. Trimebutine Lanreotide may increase the bradycardic activities of Trimebutine. Trimethadione Trimethadione may increase the bradycardic activities of Lanreotide. Troglitazone The therapeutic efficacy of Troglitazone can be decreased when used in combination with Lanreotide. Ubidecarenone The risk or severity of hypoglycemia can be increased when Lanreotide is combined with Ubidecarenone. Ubrogepant The serum concentration of Ubrogepant can be increased when it is combined with Lanreotide. Vandetanib The metabolism of Vandetanib can be decreased when combined with Lanreotide. Vardenafil The metabolism of Vardenafil can be decreased when combined with Lanreotide. Vemurafenib The metabolism of Vemurafenib can be decreased when combined with Lanreotide. Venetoclax The metabolism of Venetoclax can be decreased when combined with Lanreotide. Venlafaxine The risk or severity of hypoglycemia can be increased when Venlafaxine is combined with Lanreotide. Verapamil Verapamil may increase the bradycardic activities of Lanreotide. Vildagliptin The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Lanreotide. Vinblastine The metabolism of Vinblastine can be decreased when combined with Lanreotide. Vincristine The metabolism of Vincristine can be decreased when combined with Lanreotide. Vindesine The metabolism of Vindesine can be decreased when combined with Lanreotide. Vinflunine The metabolism of Vinflunine can be decreased when combined with Lanreotide. Vinorelbine The metabolism of Vinorelbine can be decreased when combined with Lanreotide. Vorapaxar The metabolism of Vorapaxar can be decreased when combined with Lanreotide. Voxelotor The serum concentration of Voxelotor can be increased when it is combined with Lanreotide. Warfarin The serum concentration of Warfarin can be increased when it is combined with Lanreotide. Zanubrutinib The metabolism of zanubrutinib can be decreased when combined with Lanreotide. Zimelidine The risk or severity of hypoglycemia can be increased when Zimelidine is combined with Lanreotide. Ziprasidone The metabolism of Ziprasidone can be decreased when combined with Lanreotide. Zonisamide Zonisamide may increase the bradycardic activities of Lanreotide. Zopiclone The metabolism of Zopiclone can be decreased when combined with Lanreotide. Zuclopenthixol The metabolism of Zuclopenthixol can be decreased when combined with Lanreotide. Pregnancy and Lactation AU TGA pregnancy category: C US FDA pregnancy category: Not assigned Pregnancy Limited available data based on post-marketing case reports with lanreotide use in pregnant women are not sufficient to determine a drug-associated risk of adverse developmental outcomes. In animal reproduction studies, decreased embryo/fetal survival was observed in pregnant rats and rabbits at subcutaneous doses 5- and 2-times the maximum recommended human dose (MRHD) of 120 mg, respectively (see Data). The estimated background risk of major birth defects and miscarriage for the indicated populations is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Lactation There is no information available on the presence of lanreotide in human milk, the effects of the drug on the breastfed infant, or the effects of the drug on milk production. Studies show that lanreotide administered subcutaneously passes into the milk of lactating rats; however, due to specifies-specific differences in lactation physiology, animal data may not reliably predict drug levels in human milk. Because of the potential for serious adverse reactions in breastfed infants from Lanreotide Injection, including effects on glucose metabolism and bradycardia, advise women not to breastfeed during treatment with Lanreotide Injection and for 6 months (6 half-lives) following the last dose. Why is this medication prescribed? Lanreotide injection is used to treat people with acromegaly (a condition in which the body produces too much growth hormone, causing enlargement of the hands, feet, and facial features; joint pain; and other symptoms) who have not successfully, or cannot be treated with surgery or radiation. Lanreotide injection is also used to treat people with neuroendocrine tumors in the gastrointestinal (GI) tract or the pancreas (GEP-NETs) that have spread or cannot be removed by surgery. Lanreotide injection is in a class of medications called somatostatin agonists. It works by decreasing the amounts of certain natural substances produced by the body. How should this medicine be used? Lanreotide comes as a long-acting solution (liquid) to be injected subcutaneously (under the skin) into the upper outer area of your buttock by a doctor or nurse. Lanreotide long-acting injection is usually injected once every 4 weeks. Ask your doctor or pharmacist to explain any part you do not understand. Your doctor will probably adjust your dose or the length of time between doses depending on your lab results. Ask your pharmacist or doctor for a copy of the manufacturer’s information for the patient. This medication may be prescribed for other uses; ask your doctor or pharmacist for more information. What special precautions should I follow? Before receiving lanreotide injection, tell your doctor and pharmacist if you are allergic to lanreotide injection, any other medications, or any of the ingredients in lanreotide injection. Ask your pharmacist for a list of the ingredients. tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention any of the following: beta-blockers such as atenolol (Tenormin, in Tenoretic), labetalol (Trandate), metoprolol (Lopressor, Toprol XL, in Dutoprol), nadolol (Corgard, in Corzide), and propranolol (Hemangeol, Inderal, InnoPran); bromocriptine (Cycloset, Parlodel); cyclosporine (Gengraf, Neoral, Sandimmune); insulin and oral medications for diabetes; quinidine (in Nuedexta), or terfenadine (no longer available in the U.S.). Your doctor may need to change the doses of your medications or monitor you carefully for side effects. tell your doctor if you have or have ever had diabetes, or gallbladder, heart, kidney, thyroid, or liver disease. tell your doctor if you are pregnant, plan to become pregnant, or are breastfeeding. If you become pregnant while receiving a lanreotide injection, call your doctor. you should know that lanreotide injection may make you drowsy or dizzy. Do not drive a car or operate machinery until you know how this medication affects you. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022074s011lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022074s022lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022074s006lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022074lbl.pdf https://www.cancer.gov/about-cancer/treatment/drugs/lanreotideacetate https://pubchem.ncbi.nlm.nih.gov/compound/Lanreotide https://pubchem.ncbi.nlm.nih.gov/compound/Lanreotide-acetate https://go.drugbank.com/drugs/DB06791 https://www.drugs.com/lanreotide.html https://en.wikipedia.org/wiki/Lanreotide https://www.mayoclinic.org/drugs-supplements/lanreotide-subcutaneous-route/side-effects/drg-20071321?p=1 https://medlineplus.gov/druginfo/meds/a615007.html https://www.webmd.com/drugs/2/drug-149274/lanreotide-subcutaneous/details/list-contraindications https://clinicaltrials.gov/ct2/about-site/terms-conditions#Use https://clinicaltrials.gov https://www.nlm.nih.gov/copyright.html https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=LANREOTIDE+ACETATE https://www.fda.gov/about-fda/about-website/website-policies#linking https://www.fda.gov/science-research/liver-toxicity-knowledge-base-ltkb/drug-induced-liver-injury-rank-dilirank-dataset https://www.drugbank.ca/legal/terms_of_use https://www.drugbank.ca/drugs/DB06791 https://www.nlm.nih.gov/copyright.html https://www.cancer.gov/policies/copyright-reuse https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C1523 https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C74584 https://www.epa.gov/privacy/privacy-act-laws-policies-and-resources https://comptox.epa.gov/dashboard/DTXSID201027706 https://comptox.epa.gov/dashboard/DTXSID60897514 https://echa.europa.eu/web/guest/legal-notice https://echa.europa.eu/information-on-chemicals https://echa.europa.eu/information-on-chemicals/cl-inventory-database/-/discli/details/221249 https://echa.europa.eu/information-on-chemicals/cl-inventory-database/-/discli/details/228509 https://www.ema.europa.eu/en/about-us/legal-notice https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001503-pip01-13 https://www.guidetopharmacology.org/about.jsp#license https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2031 https://www.guidetopharmacology.org/targets.jsp https://idrblab.net/ttd/data/drug/details/D0M2YE https://www.clinicaltrialsregister.eu/ https://www.fda.gov/about-fda/about-website/website-policies#linking https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book http://www.hmdb.ca/citing http://www.hmdb.ca/metabolites/HMDB0253977 https://www.metabolomicsworkbench.org/data/StructureData.php?RegNo=149987 https://www.fda.gov/about-fda/about-website/website-policies#linking https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory https://www.cancer.gov/policies/copyright-reuse https://www.cancer.gov/about-cancer/treatment/drugs/lanreotideacetate NIPH Clinical Trials Search of Japan https://rctportal.niph.go.jp/en/ https://www.nlm.nih.gov/research/umls/rxnorm/docs/termsofservice.html https://rxnav.nlm.nih.gov/id/rxnorm/68092 https://rxnav.nlm.nih.gov/id/rxnorm/236167 https://pubchem.ncbi.nlm.nih.gov https://pubchem.ncbi.nlm.nih.gov/substance/?source=15745&sourceid=77084017-740927991 https://www.whocc.no/copyright_disclaimer/ https://www.whocc.no/atc/ https://www.whocc.no/atc_ddd_index/ https://www.nlm.nih.gov/copyright.html https://www.ncbi.nlm.nih.gov/mesh/67060347 http://www.nlm.nih.gov/mesh/meshhome.html https://www.ncbi.nlm.nih.gov/mesh/68000970 http://www.unece.org/trans/danger/publi/ghs/ghs_welcome_e.html https://creativecommons.org/licenses/by/4.0/ https://www.norman-network.com/nds/SLE/ https://pubchem.ncbi.nlm.nih.gov/substance/389019395 https://www.ncbi.nlm.nih.gov/books/n/livertox/Lanreotide/ References